Aeglea BioTherapeutics Current Ratio 2015-2021 | AGLE

Aeglea BioTherapeutics current ratio from 2015 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Aeglea BioTherapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.13B $0.02B 6.52
2021-03-31 $0.15B $0.03B 4.68
2020-12-31 $0.15B $0.02B 9.11
2020-09-30 $0.14B $0.01B 10.06
2020-06-30 $0.16B $0.02B 10.19
2020-03-31 $0.05B $0.02B 3.17
2019-12-31 $0.08B $0.02B 4.06
2019-09-30 $0.09B $0.02B 6.02
2019-06-30 $0.11B $0.01B 8.44
2019-03-31 $0.13B $0.01B 10.74
2018-12-31 $0.08B $0.01B 7.49
2018-09-30 $0.07B $0.01B 9.37
2018-06-30 $0.08B $0.01B 12.78
2018-03-31 $0.05B $0.01B 8.47
2017-12-31 $0.06B $0.01B 9.77
2017-09-30 $0.06B $0.01B 12.20
2017-06-30 $0.07B $0.00B 14.99
2017-03-31 $0.06B $0.00B 15.24
2016-12-31 $0.07B $0.00B 16.75
2016-09-30 $0.07B $0.00B 18.68
2016-06-30 $0.08B $0.00B 22.88
2016-03-31 $0.04B $0.00B 9.22
2015-12-31 $0.04B $0.00B 15.18
2015-09-30 $0.00B 0.00
2015-06-30 $0.00B 0.00
2015-03-31 $0.00B 0.00
2014-12-31 $0.00B $0.00B 2.60
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.372B $0.004B
Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86